Impact of corticosteroid use on comorbidities in patients with myasthenia gravis in the US National Veterans Affairs Health Network
Increased risks for the development of key comorbidities among patients with MG were associated with corticosteroid use, particularly at higher-dose intensities. Our findings support strategies to minimize corticosteroid usage in MG.
Authors
- Femke De Ruyck
- Deborah Gelinas
- Tuan Vu (ORCID: https://orcid.org/0000-0003-0724-0210)
- C. Blein (ORCID: https://orcid.org/0000-0003-0900-8351)
- Alexis Lizarraga (ORCID: https://orcid.org/0000-0003-1418-9775)
- Lizheng Shi
- Cynthia Z. Qi (ORCID: https://orcid.org/0009-0007-9096-3570)
- Yuebing Li (ORCID: https://orcid.org/0000-0002-4248-8927)
- Yilu Lin
Institutions
- Tulane University (US)
- Cleveland Clinic (US)
- University of South Florida (US)
- University of Rochester Medical Center (US)
- Southeast Louisiana Veterans Health Care System (US)
- IDEX Corporation (United States) (US)
- Argenx (Belgium) (BE)
- University of Rochester (US)
Publication Details
- Journal
- Journal of the Neurological Sciences
- Published
- 2026-01-07
- DOI
- https://doi.org/10.1016/j.jns.2025.125716
- Citations
- 3
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 117.46